Role of l-arginine/nitric oxide/cyclic GMP/KATP channel signaling pathway and opioid receptors in the antinociceptive effect of rutin in mice.
Journal
Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
The l-arginine (l-Arg)/nitric oxide/cyclic GMP/potassium channel (KATP) pathway and opioid receptors are known to play critical roles in pain perception and the antinociceptive effects of various compounds. While there is evidence suggesting that the analgesic effects of rutin may involve nitric oxide modulation, the direct link between rutin and the l-Arg/nitric oxide/cyclic GMP/KATP pathway in the context of pain modulation requires further investigation. The antinociceptive effect of rutin was studied in male NMRI mice using the formalin test. To investigate the role of the l-Arg/nitric oxide/cyclic GMP/KATP pathway and opioid receptors, the mice were pretreated intraperitoneally with different substances. These substances included l-Arg (a precursor of nitric oxide), S-nitroso-N-acetylpenicillamine (SNAP, a nitric oxide donor), N(gamma)-nitro-l-arginine methyl ester (L-NAME, an inhibitor of nitric oxide synthase), sildenafil (an inhibitor of phosphodiesterase enzyme), glibenclamide (a KATP channel blocker), and naloxone (an opioid receptor antagonist). All pretreatments were administered 20 min before the administration of the most effective dose of rutin. Based on our investigation, it was found that rutin exhibited a dose-dependent antinociceptive effect. The administration of SNAP enhanced the analgesic effects of rutin during both the initial and secondary phases. Moreover, L-NAME, naloxone, and glibenclamide reduced the analgesic effects of rutin in both the primary and secondary phases. In conclusion, rutin holds significant value as a flavonoid with analgesic properties, and its analgesic effect is directly mediated through the nitric oxide/cyclic GMP/KATP channel pathway.
Identifiants
pubmed: 39230435
doi: 10.1097/FBP.0000000000000792
pii: 00008877-990000000-00099
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Alonso-Castro AJ, Rangel-Velázquez JE, Isiordia-Espinoza MA, Villanueva-Solís LE, Aragon-Martinez OH, Zapata-Morales JR (2017). Synergism between naproxen and rutin in a mouse model of visceral pain. Drug Dev Res 78:184–188.
Babbedge R, Hart S, Moore P (1993). Anti‐nociceptive activity of nitric oxide synthase inhibitors in the mouse: dissociation between the effect of L‐NAME and L‐NMMA. J Pharm Pharmacol 45:77–79.
Baron R, Binder A, Wasner G (2010). Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9:807–819.
Bonica J (1990). The management of pain. 2nd ed. Philadelphia: Lea and Febriger. pp. 1878–1883.
Carvalho TT, Mizokami SS, Ferraz CR, Manchope MF, Borghi SM, Fattori V, et al. (2019). The granulopoietic cytokine granulocyte colony-stimulating factor (G-CSF) induces pain: analgesia by rutin. Inflammopharmacology 27:1285–1296.
Costigan M, Scholz J, Woolf CJ (2009). Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 32:1–32.
Cury Y, Picolo G, Gutierrez VP, Ferreira SH (2011). Pain and analgesia: the dual effect of nitric oxide in the nociceptive system. Nitric Oxide 25:243–254.
Dal D, Salman MA, Salman AE, Iskit AB, Aypar U (2006). The involvement of nitric oxide on the analgesic effect of tramadol. Eur J Anaesthesiol 23:175–177.
Dickenson AH, Sullivan AF (1987). Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain 30:349–360.
Duarte ID, Ferreira SH (2000). L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. Mediators Inflamm 9:25–30.
Dubuisson D, Dennis SG (1977). The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4:161–174.
Fakhri S, Ahmadpour Y, Rezaei H, Kooshki L, Moradi SZ, Iranpanah A, et al. (2020). The antinociceptive mechanisms of melatonin: role of l-arginine/nitric oxide/cyclic GMP/KATP channel signaling pathway. Behav Pharmacol 31:728–737.
Fang XX, Zhai MN, Zhu M, He C, Wang H, Wang J, Zhang Z-J (2023). Inflammation in pathogenesis of chronic pain: foe and friend. Mol Pain 19:17448069231178176.
Ferraz CR, Carvalho TT, Manchope MF, Artero NA, Rasquel-Oliveira FS, Fattori V, et al. (2020). Therapeutic potential of flavonoids in pain and inflammation: mechanisms of action, pre-clinical and clinical data, and pharmaceutical development. Molecules 25:762.
Ganeshpurkar A, Saluja AK (2017). The pharmacological potential of rutin. Saudi Pharm J 25:149–164.
Han Y (2009). Rutin has therapeutic effect on septic arthritis caused by Candida albicans. Int Immunopharmacol 9:207–211.
Hasanein P, Emamjomeh A, Chenarani N, Bohlooli M (2020). Beneficial effects of rutin in diabetes-induced deficits in acquisition learning, retention memory and pain perception in rats. Nutr Neurosci 23:563–574.
Hernandez‐Leon A, Fernández‐Guasti A, González‐Trujano M (2016). Rutin antinociception involves opioidergic mechanism and descending modulation of ventrolateral periaqueductal grey matter in rats. Eur J Pain 20:274–283.
Horcajada M-N, Sanchez C, Scalfo FM, Drion P, Comblain F, Taralla S, et al. (2015). Oleuropein or rutin consumption decreases the spontaneous development of osteoarthritis in the Hartley guinea pig. Osteoarthritis Cartilage 23:94–102.
Koohsari S, Sheikholeslami MA, Parvardeh S, Ghafghazi S, Samadi S, Poul YK, et al. (2020). Antinociceptive and antineuropathic effects of cuminaldehyde, the major constituent of Cuminum cyminum seeds: possible mechanisms of action. J Ethnopharmacol 255:112786.
Koval’Skii I, Krasnyuk I, Krasnyuk I, Nikulina O, Belyatskaya A, Kharitonov YY, et al. (2014). Mechanisms of rutin pharmacological action. Pharm Chem J 48:73–76.
McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, et al. (2007). TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci USA 104:13525–13530.
Miclescu A, Gordh T (2009). Nitric oxide and pain: ‘Something old, something new’. Acta Anaesthesiol Scand 53:1107–1120.
Mohammadi S, Fakhri S, Mohammadi-Farani A, Farzaei MH, Abbaszadeh F (2021). Astaxanthin engages the l-arginine/NO/cGMP/KATP channel signaling pathway toward antinociceptive effects. Behav Pharmacol 32:607–614.
Moradi N, Fakhri S, Farzaei MH, Abbaszadeh F (2021). The anti-nociceptive activity of naringenin passes through l-arginine/NO/cGMP/KATP channel pathway and opioid receptors. Behav Pharmacol 32:590–598.
Morino K, Matsukura N, Kawachi T, Ohgaki H, Sugimura T, Hirono I (1982). Carcinogenicity test of quercetin and rutin in golden hamsters by oral administration. Carcinogenesis 3:93–97.
Morteza-Semnani K, Saeedi M, Hamidian M, Vafamehr H, Dehpour AR (2002). Anti-inflammatory, analgesic activity and acute toxicity of Glaucium grandiflorum extract. J Ethnopharmacol 80:181–186.
Muvhulawa N, Dludla PV, Ziqubu K, Mthembu SXH, Mthiyane F, Nkambule BB, Mazibuko-Mbeje SE (2022). Rutin ameliorates inflammation and improves metabolic function: a comprehensive analysis of scientific literature. Pharmacol Res 178:106163.
Nieoczym D, Socała K, Raszewski G, Wlaź P (2014). Effect of quercetin and rutin in some acute seizure models in mice. Prog Neuropsychopharmacol Biol Psychiatry 54:50–58.
Nikfarjam BA, Adineh M, Hajiali F, Nassiri-Asl M (2017). Treatment with rutin – a therapeutic strategy for neutrophil-mediated inflammatory and autoimmune diseases. J Pharmacopuncture 20:52–56.
Ostrakhovitch EA, Afanas’ev IB (2001). Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other antioxidants and chelators. Biochem Pharmacol 62:743–746.
Parvardeh S, Sabetkasaei M, Moghimi M, Masoudi A, Ghafghazi S, Mahboobifard F (2018). Role of l-arginine/NO/cGMP/K(ATP) channel signaling pathway in the central and peripheral antinociceptive effect of thymoquinone in rats. Iran J Basic Med Sci 21:625–633.
Safaripour S, Nemati Y, Parvardeh S, Ghafghazi S, Fouladzadeh A, Moghimi M (2018). Role of l-arginine/SNAP/NO/cGMP/KATP channel signalling pathway in antinociceptive effect of α-terpineol in mice. J Pharm Pharmacol 70:507–515.
Satari A, Ghasemi S, Habtemariam S, Asgharian S, Lorigooini Z (2021). Rutin: a flavonoid as an effective sensitizer for anticancer therapy; insights into multifaceted mechanisms and applicability for combination therapy. Evid Based Complement Alternat Med 2021:9913179.
Selvaraj G, Kaliamurthi S, Thirungnasambandam R, Vivekanandan L, Balasubramanian T (2014). Anti-nociceptive effect in mice of thillai flavonoid rutin. Biomed Environ Sci 27:295–299.
Sheikholeslami MA, Ghafghazi S, Parvardeh S, Koohsari S, Aghajani SH, Pouriran R, Vaezi LA (2021). Analgesic effects of cuminic alcohol (4-isopropylbenzyl alcohol), a monocyclic terpenoid, in animal models of nociceptive and neuropathic pain: role of opioid receptors, l-arginine/NO/cGMP pathway, and inflammatory cytokines. Eur J Pharmacol 900:174075.
Shibata M, Ohkubo T, Takahashi H, Inoki R (1989). Modified formalin test: characteristic biphasic pain response. Pain 38:347–352.
Smart KM, Blake C, Staines A, Doody C (2010). Clinical indicators of ‘nociceptive’, ‘peripheral neuropathic’ and ‘central’ mechanisms of musculoskeletal pain. A Delphi survey of expert clinicians. Man Ther 15:80–87.
Tian C, Liu X, Chang Y, Wang R, Yang M, Liu M (2021). Rutin prevents inflammation induced by lipopolysaccharide in RAW 264.7 cells via conquering the TLR4-MyD88-TRAF6-NF-κB signalling pathway. J Pharm Pharmacol 73:110–117.
Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K (1992). The formalin test: an evaluation of the method. Pain 51:5–17.
Yalcin I, Aksu F (2005). Involvement of potassium channels and nitric oxide in tramadol antinociception. Pharmacol Biochem Behav 80:69–75.